Hikma Pharmaceuticals (LON:HIK) Earns "Buy" Rating from Jefferies Financial Group

Key Points

• Jefferies reissued a “Buy” rating on Hikma Pharmaceuticals and set a GBX 2,025 price target, implying 25.93% upside from the prior close.
• Analyst sentiment remains broadly positive: six analysts rate the stock “Buy,” with a consensus price target of GBX 2,085.83.
• Hikma shares opened at GBX 1,608, while insider Tobias Hestler purchased 7,500 shares for approximately £123,600; insiders own 22.26% of the company.

Hikma Pharmaceuticals (LON:HIK - Get Free Report)'s stock had its "buy" rating reissued by research analysts at Jefferies Financial Group in a note issued to investors on Friday, Digital Look reports. They currently have a GBX 2,025 price objective on the stock. Jefferies Financial Group's target price points to a potential upside of 25.93% from the company's previous close.

Several other equities analysts also recently commented on HIK. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a report on Friday, August 7th. Citigroup raised their target price on shares of Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a "buy" rating in a research note on Wednesday, August 12th. Finally, Berenberg Bank lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a "buy" rating in a report on Tuesday, August 11th. Six analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of GBX 2,085.83.

Hikma Pharmaceuticals Stock Performance

HIK opened at GBX 1,608 on Friday. Hikma Pharmaceuticals has a 12-month low of GBX 1,187 and a 12-month high of GBX 1,865. The business has a 50 day moving average of GBX 1,602.32 and a 200-day moving average of GBX 1,475.50. The company has a quick ratio of 1.27, a current ratio of 1.98 and a debt-to-equity ratio of 77.57. The stock has a market cap of £3.33 billion, a price-to-earnings ratio of 9.14, a PEG ratio of 2.38 and a beta of 0.66.

Insider Buying and Selling

In other Hikma Pharmaceuticals news, insider Tobias Hestler acquired 7,500 shares of the company's stock in a transaction on Monday, August 10th. The stock was acquired at an average price of GBX 1,648 per share, for a total transaction of £123,600. Corporate insiders own 22.26% of the company's stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.